MAPT and Lewy body dementia: However, owing to the heterogeneity and complexity of underlying proteinopathies and clinical symptoms in probable DLB, individualized combination therapies with acetyl-cholinesterase inhibitors,45 lifestyle interventions, treatment of age-related comorbidities, and anti-tau treatments will need to be considered.